Company / Free Cash Flow
Krystal Biotech, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$188.9M
FY2025
5-year range
-$153.5M / $188.9M
FY2021-FY2025
Trend
+58.5%
vs FY2024
Sector context
#35 of 194
Health Care
What the data says
Krystal Biotech, Inc.'s free cash flow of $189M is higher than 82% of companies in the Health Care sector (FY2025). Free Cash Flow has increased for 3 consecutive years, from -$154M in FY2022 to $189M in FY2025.
Based on SEC 10-K filings.
$189M in FY2025. Top quartile in the Health Care sector.
Improved from -$101M to $189M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 194This company $188.9M Sector average $470.6M
▼
-59.9% below sector average
Key checks
Key Insights
- Krystal Biotech, Inc.'s free cash flow has grown for 3 consecutive years.
- In FY2025, free cash flow increased 58.5% year-over-year.
- Ranks #35 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $188.9M | +58.5% |
| FY2024 | $119.2M | +218.5% |
| FY2023 | -$100.6M | +34.5% |
| FY2022 | -$153.5M | -32.1% |
| FY2021 | -$116.3M | -184.1% |
| FY2020 | -$40.9M | -63.1% |
| FY2019 | -$25.1M | -114.8% |
| FY2018 | -$11.7M | -184.9% |
| FY2017 | -$4.1M | -209.2% |
| FY2016 | -$1.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026